ClinicalTrials.gg
RecruitingNCT06613698STARLIGHTUpdated Nov 13, 2026

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

A Phase 2 interventional study of GSK4532990 and Placebo in Liver Diseases, Alcoholic, sponsored by GlaxoSmithKline. Recruiting at 150 sites in 19 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Updated Nov 13, 2026First site in ThailandStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
350
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Liver Diseases, Alcoholic with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Liver Diseases, Alcoholic · United States.

Planned enrollment
Largest of 16
350 · median 41
Started
2024
with 1 other
Phase 2
5 of 23
2 open now
Registered
22nd of 23
by date
Lead sponsor
2 of 23
GlaxoSmithKline

Among the 23 studies in Liver Diseases, Alcoholic with a site in United States, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 22nd registered.

Liver Diseases, Alcoholic

74 studies on the registry are indexed under Liver Diseases, Alcoholic; 25 are open to participants now.

Browse Liver Diseases, Alcoholic studies →

Open to participants now

7 of the 23 studies in Liver Diseases, Alcoholic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Liver Diseases, Alcoholic studies recruiting now, 7 (39%) set no upper age limit and 7 (39%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Liver Diseases, Alcoholic with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

03

Conditions studied

  • Liver Diseases, Alcoholic

Keywords

  • GSK4532990
  • Alcohol-related liver disease
  • Steatohepatitis
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 70 years of age inclusive, at the time of screening. (Participants in South Korea must be greater than or equal to [>=] 19 years of age and participants in Japan must be >= 20 years of age.)
  • Capable of giving signed prior to the performance of any study-specific procedures.
  • Able and willing to comply with all study assessments and adhere to the protocol schedule of activities.
  • In the opinion of the investigator, there is a history of alcohol consumption compatible with either ALD or Met ALD.
  • A female participant is eligible to participate after meeting additional pre-defined criteria.
  • Participants must meet predefined stable use requirements of concomitant medications based on study criteria.
  • Participant has advanced chronic liver disease

Exclusion criteria

Exclusion Criteria:

  • Meeting any definition of organ system failure as defined by the North American Consortium for Study of End-stage Liver Disease (NACSELD)
  • Exceeding pre-defined biochemical parameters for , AST, ALP, , , Albumin, , UACR or . Other primary causes of liver disease based on study criteria.
  • Current (except for basal cell carcinoma or uterine carcinoma-in-situ) at screening. Participants under evaluation for possible malignancy at screening are not eligible.
  • Prior organ transplant (except for corneal transplants).
  • Chronic or acute, including partial, known portal vein thrombosis.
  • Prior Transjugular Intrahepatic Portosystemic Shunt (TIPSS) insertion.
  • Any acute cardiovascular event including myocardial infarction, unstable angina, symptomatic heart failure, or cerebrovascular accident in the 6 months prior to screening.
  • Poorly controlled hypertension
  • Clinical suspicion of rhabdomyolysis during the screening period
  • Clinical suspicion of a bleeding episode during the screening period related to portal hypertension and/or low blood fibrinogen level.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    GSK4532990 Dose 1

    Drug: GSK4532990

  • Experimental
    GSK4532990 Dose 2

    Drug: GSK4532990

  • Experimental
    GSK4532990 Dose 3

    Drug: GSK4532990

  • Experimental
    GSK4532990 Dose 4

    Drug: GSK4532990

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • GSK4532990 will be administered

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 8 weeks

  2. Number of participants with potentially clinically relevant changes in electrocardiogram (ECG), vital signs, and clinical laboratory tests.

    Time frame: Up to 8 weeks

  3. Change from baseline in Liver Stiffness measurement (LSM) reduction using FibroScan® at Week 52 (kiloPascal)

    Liver stiffness will be measured by vibration-controlled transient elastography (VCTE) using the FibroScan® device.

    Time frame: Baseline (Day 1) and at Week 52

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of GSK4532990

    Time frame: Up to Day 4

  2. Area Under the Curve from Time 0 to t [AUC (0-t)] of GSK4532990

    Time frame: Up to Day 4

  3. Area Under the Curve from Time 0 to 24 hours [AUC (0-24)] of GSK4532990

    Time frame: Up to 24 hours

  4. Plasma half-life (t1/2) of GSK4532990

    Time frame: Up to Day 4

  5. Apparent clearance (CL/F) of GSK4532990

    Time frame: Up to Day 4

  6. Time to maximum concentration (tmax) of GSK4532990

    Time frame: Up to Day 4

  7. Apparent terminal phase volume of distribution (Vz/F) of GSK4532990

    Time frame: Up to Day 4

  8. Change from baseline in serum AST at Week 52

    Time frame: Baseline (Day 1), and at Week 52

  9. Change from baseline in Enhanced Liver Fibrosis (ELFTM) score at Week 52

    The ELFTM score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers, including tissue inhibitor of metalloproteinases-1 (TIMP-1), type III procollagen (PIIINP), and hyaluronic acid (HA). The ELFTM score is used as a prognostic marker for disease progression. ELFTM score will range between 4.5 to 14.7. A higher ELFTM score will predict worse prognosis

    Time frame: Baseline (Day 1), and at Week 52

  10. Change from baseline in model for end-stage liver disease (MELD) score at Week 52

    MELD is a scoring system for assessing the severity of chronic liver disease. MELD scores range between 6 and 40, with 40 being the most severe.

    Time frame: Baseline (Day 1), and at Week 52

  11. Change from baseline in LSM using FibroScan® at Week 52 (kiloPascal)

    Time frame: Baseline (Day 1), and at Week 52

  12. Area under the concentration-time curve from time zero (pre-dose) to the last quantifiable concentration (AUC0-t) of GSK4532990

    Time frame: Up to Day 3

  13. Maximum observed plasma concentration (Cmax) of GSK4532990

    Time frame: Up to Day 3

07

Study locations

148 of 150 sites recruiting
  • GSK Investigational Site
    Chandler, Arizona 85224-4711, United States
    Recruiting
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
    Recruiting
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
    Recruiting
  • GSK Investigational Site
    Tucson, Arizona 85715, United States
    Recruiting
  • GSK Investigational Site
    Coronado, California 92118-1408, United States
    Recruiting
  • GSK Investigational Site
    Lancaster, California 93534, United States
    Recruiting
  • GSK Investigational Site
    Los Angeles, California 90033, United States
    Recruiting
  • GSK Investigational Site
    Los Angeles, California 90048, United States
    Recruiting
  • GSK Investigational Site
    Pasadena, California 91105-2561, United States
    Recruiting
  • GSK Investigational Site
    Sacramento, California 95817-1348, United States
    Recruiting
  • GSK Investigational Site
    Brandon, Florida 33511, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33173, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Atlanta, Georgia 30309, United States
    Recruiting
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
    Recruiting
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
    Recruiting
  • GSK Investigational Site
    Marrero, Louisiana 70072, United States
    Recruiting
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
    Recruiting
  • GSK Investigational Site
    Las Vegas, Nevada 89106, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10029, United States
    Recruiting
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
    Recruiting
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19014, United States
    Recruiting
  • GSK Investigational Site
    Hermitage, Tennessee 37076, United States
    Recruiting
  • GSK Investigational Site
    Arlington, Texas 76012, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78757-8066, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75203, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75390-7208, United States
    Recruiting
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
    Recruiting
  • GSK Investigational Site
    Georgetown, Texas 78626, United States
    Recruiting
  • GSK Investigational Site
    McAllen, Texas 78503, United States
    Completed

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    San Antonio, Texas 78215, United States
    Recruiting
  • GSK Investigational Site
    Richmond, Virginia 23219, United States
    Recruiting
  • GSK Investigational Site
    Richmond, Virginia 23249-0001, United States
    Recruiting
  • GSK Investigational Site
    Buenos Aires, 1425, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1061AAS, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1181ACH, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad AutOnoma de Buenos Aire, 1118, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1426, Argentina
    Recruiting
  • GSK Investigational Site
    Rosario, 2002, Argentina
    Recruiting
  • GSK Investigational Site
    Rosario, S2002, Argentina
    Recruiting
  • GSK Investigational Site
    San Miguel de Tucumán, T4000IHE, Argentina
    Recruiting
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
    Recruiting
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • GSK Investigational Site
    Parkville Melbourne, Victoria 3050, Australia
    Recruiting
  • GSK Investigational Site
    Murdoch, Western Australia 6150, Australia
    Recruiting
  • GSK Investigational Site
    Perth, Western Australia 6000, Australia
    Recruiting
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
    Recruiting
  • GSK Investigational Site
    Edmonton, Alberta T5L 4G4, Canada
    Recruiting
  • GSK Investigational Site
    New Westminster, British Columbia V3L 3W4, Canada
    Recruiting
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2K5, Canada
    Recruiting
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M1S 4T7, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
  • GSK Investigational Site
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
  • GSK Investigational Site
    Terrebonne, Quebec J6X 4P7, Canada
    Recruiting
  • GSK Investigational Site
    Esbjerg, 6700, Denmark
    Recruiting
  • GSK Investigational Site
    Hvidovre, 2650, Denmark
    Recruiting
  • GSK Investigational Site
    Odense C, 5000, Denmark
    Recruiting
  • GSK Investigational Site
    Angers, 49933, France
    Recruiting
  • GSK Investigational Site
    Bobigny, 93000, France
    Recruiting
  • GSK Investigational Site
    Créteil, 94000, France
    Recruiting
  • GSK Investigational Site
    Lille, 59037, France
    Recruiting
  • GSK Investigational Site
    Montpellier, 34295, France
    Recruiting
  • GSK Investigational Site
    Rouen, 76031, France
    Recruiting
  • GSK Investigational Site
    Bochum, North Rhine-Westphalia 44892, Germany
    Recruiting
  • GSK Investigational Site
    Homburg, Saarland 66421, Germany
    Recruiting
  • GSK Investigational Site
    Leipzig, Saxony 04103, Germany
    Recruiting
  • GSK Investigational Site
    Berlin, 10787, Germany
    Recruiting
  • GSK Investigational Site
    Berlin, 13353, Germany
    Recruiting
  • GSK Investigational Site
    Kiel, 24105, Germany
    Recruiting
  • GSK Investigational Site
    Leipzig, 04103, Germany
    Recruiting
  • GSK Investigational Site
    Mainz, 55101, Germany
    Recruiting
  • GSK Investigational Site
    Athens, 10676, Greece
    Recruiting
  • GSK Investigational Site
    Athens, 11527, Greece
    Recruiting
  • GSK Investigational Site
    Athens, 11527, Greece
    Recruiting
  • GSK Investigational Site
    Bergamo, 24127, Italy
    Recruiting
  • GSK Investigational Site
    Bologna, 40138, Italy
    Recruiting
  • GSK Investigational Site
    Messina, 98124, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20122, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20142, Italy
    Recruiting
  • GSK Investigational Site
    Milan, 20162, Italy
    Recruiting
  • GSK Investigational Site
    Padova, 35131, Italy
    Recruiting
  • GSK Investigational Site
    Roma, 00128, Italy
    Recruiting
  • GSK Investigational Site
    Roma, 00168, Italy
    Recruiting
  • GSK Investigational Site
    Chiba, 286-8520, Japan
    Recruiting
  • GSK Investigational Site
    Ehime, 790-0024, Japan
    Recruiting
  • GSK Investigational Site
    Gunma, 371-8511, Japan
    Recruiting
  • GSK Investigational Site
    Hokkaido, 060-0033, Japan
    Recruiting
  • GSK Investigational Site
    Kagawa, 760-0017, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Kagawa, 761-0793, Japan
    Recruiting
  • GSK Investigational Site
    Nara, 634-8522, Japan
    Recruiting
  • GSK Investigational Site
    Niigata, 951-8520, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 545-8586, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 564-0013, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 565-0871, Japan
    Recruiting
  • GSK Investigational Site
    Saitama, 350-0495, Japan
    Recruiting
  • GSK Investigational Site
    Shizuoka, 431-3192, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 180-8610, Japan
    Recruiting

Showing the first 100 of 150 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Nov 2027, 37 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2028 → Mar 2029, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 26, 2024
StartActual
Sep 27, 2024
Primary completionEst.
Nov 26, 2027
CompletionEst.
Mar 2, 2029was Mar 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added, 4 sites removed — first site in Thailand
Show 14 added (4 Spain, 3 Thailand, 2 Germany, 2 Mexico, 1 Canada, 1 Poland, 1 South Africa)
  • GSK Investigational Site · Edmonton, Canada
  • GSK Investigational Site · Homburg, Germany
  • GSK Investigational Site · Leipzig, Germany
  • GSK Investigational Site · San Pedro Garza García, Mexico
  • GSK Investigational Site · Mexico City, Mexico
  • GSK Investigational Site · Katowice, Poland
  • GSK Investigational Site · Johannesburg, South Africa
  • GSK Investigational Site · Alcorcon Madrid, Spain
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Madrid, Spain
  • GSK Investigational Site · Zaragoza, Spain
  • GSK Investigational Site · Chiang Mai, Thailand
  • GSK Investigational Site · Khon Kaen, Thailand
  • GSK Investigational Site · Songkhla, Thailand
Show 4 removed
  • GSK Investigational Site · DF, Mexico
  • GSK Investigational Site · San Pedro Garza García, Mexico
  • GSK Investigational Site · Katowice, Poland
  • GSK Investigational Site · Soweto Johannesburg, South Africa
Nov 13, 2026
Study completion
Mar 7, 2028→Mar 2, 2029
Nov 13, 2026
Enrollment
393→350
Nov 13, 2026
Eligibility
1 inclusion criterion added; 2 exclusion criteria edited, 2 removed
What changed in the criteria
Inclusion criteria
  • AddedParticipant must be 18 to 70 years of age inclusive, at the time of screening. (Participants in South Korea must be greater than or equal to [>=] 19 years of age and participants in Japan must be >= 20 years of age.)
Exclusion criteria
  • EditedExceeding pre-defined biochemical parameters for Alanine Aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline Phosphatase (ALP), Platelets, International normalised ratio (INR), Albumin, estimated glomerular filtration rate (eGFR), Urine albumin-creatinine ratio (UACR) or Glycosylated Hemoglobin (HbA1c). Other primary causes of liver disease based on study criteria.
  • EditedPrior organ transplant or current listing or active consideration for organ transplant during the screening period (except for corneal transplants).
  • RemovedBody Mass Index (BMI) >35 kg/m2 at screening
  • RemovedAny liver-related clinical event that started (onset) <8 weeks prior to Baseline (D1).
Nov 13, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 removed
What changed in the outcomes
  • EditedNumber of participants with potentially clinically relevant changes in electrocardiogram (ECG), vital signs, and clinical laboratory tests.Time frame: Up to 8 weeks
  • RemovedChange from baseline in model for end-stage liver disease (MELD) score reduction at Week 52Time frame: Baseline (Day 1) and up to Week 52
  • Time frameChange from baseline in Liver Stiffness measurement (LSM) reduction using FibroScan® at Week 52 (kiloPascal)Baseline (Day 1) and up to Week 52 → Baseline (Day 1) and at Week 52
Nov 13, 2026
Secondary outcomes
1 edited, 2 added
What changed in the outcomes
  • EditedChange from baseline in Enhanced Liver Fibrosis (ELF™ELFTM) score at Week 52Time frame: Baseline (Day 1), and at Week 52
  • AddedChange from baseline in model for end-stage liver disease (MELD) score at Week 52Time frame: Baseline (Day 1), and at Week 52
  • AddedChange from baseline in LSM using FibroScan® at Week 52 (kiloPascal)Time frame: Baseline (Day 1), and at Week 52
Nov 13, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • GSK Investigational Site · Leipzig, GermanyContact person changed (no phone or email listed)
  • GSK Investigational Site · León, SpainContact person changed (no phone or email listed)
  • GSK Investigational Site · Madrid, SpainContact person changed (no phone or email listed)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    14 sites added, 4 sites removed — first site in Thailand
    Show 14 added (4 Spain, 3 Thailand, 2 Germany, 2 Mexico, 1 Canada, 1 Poland, 1 South Africa)
    • GSK Investigational Site · Edmonton, Canada
    • GSK Investigational Site · Homburg, Germany
    • GSK Investigational Site · Leipzig, Germany
    • GSK Investigational Site · San Pedro Garza García, Mexico
    • GSK Investigational Site · Mexico City, Mexico
    • GSK Investigational Site · Katowice, Poland
    • GSK Investigational Site · Johannesburg, South Africa
    • GSK Investigational Site · Alcorcon Madrid, Spain
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Madrid, Spain
    • GSK Investigational Site · Zaragoza, Spain
    • GSK Investigational Site · Chiang Mai, Thailand
    • GSK Investigational Site · Khon Kaen, Thailand
    • GSK Investigational Site · Songkhla, Thailand
    Show 4 removed
    • GSK Investigational Site · DF, Mexico
    • GSK Investigational Site · San Pedro Garza García, Mexico
    • GSK Investigational Site · Katowice, Poland
    • GSK Investigational Site · Soweto Johannesburg, South Africa
    Study completion Mar 7, 2028→Mar 2, 2029
    Enrollment 393→350
    Eligibility 1 inclusion criterion added; 2 exclusion criteria edited, 2 removed
    What changed in the criteria
    Inclusion criteria
    • AddedParticipant must be 18 to 70 years of age inclusive, at the time of screening. (Participants in South Korea must be greater than or equal to [>=] 19 years of age and participants in Japan must be >= 20 years of age.)
    Exclusion criteria
    • EditedExceeding pre-defined biochemical parameters for Alanine Aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline Phosphatase (ALP), Platelets, International normalised ratio (INR), Albumin, estimated glomerular filtration rate (eGFR), Urine albumin-creatinine ratio (UACR) or Glycosylated Hemoglobin (HbA1c). Other primary causes of liver disease based on study criteria.
    • EditedPrior organ transplant or current listing or active consideration for organ transplant during the screening period (except for corneal transplants).
    • RemovedBody Mass Index (BMI) >35 kg/m2 at screening
    • RemovedAny liver-related clinical event that started (onset) <8 weeks prior to Baseline (D1).
    Primary outcomes 1 edited, 1 time frame changed, 1 removed
    What changed in the outcomes
    • EditedNumber of participants with potentially clinically relevant changes in electrocardiogram (ECG), vital signs, and clinical laboratory tests.Time frame: Up to 8 weeks
    • RemovedChange from baseline in model for end-stage liver disease (MELD) score reduction at Week 52Time frame: Baseline (Day 1) and up to Week 52
    • Time frameChange from baseline in Liver Stiffness measurement (LSM) reduction using FibroScan® at Week 52 (kiloPascal)Baseline (Day 1) and up to Week 52 → Baseline (Day 1) and at Week 52
    Secondary outcomes 1 edited, 2 added
    What changed in the outcomes
    • EditedChange from baseline in Enhanced Liver Fibrosis (ELF™ELFTM) score at Week 52Time frame: Baseline (Day 1), and at Week 52
    • AddedChange from baseline in model for end-stage liver disease (MELD) score at Week 52Time frame: Baseline (Day 1), and at Week 52
    • AddedChange from baseline in LSM using FibroScan® at Week 52 (kiloPascal)Time frame: Baseline (Day 1), and at Week 52
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • GSK Investigational Site · Leipzig, GermanyContact person changed (no phone or email listed)
    • GSK Investigational Site · León, SpainContact person changed (no phone or email listed)
    • GSK Investigational Site · Madrid, SpainContact person changed (no phone or email listed)
    + 4 other changes: identifiers, verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06613698
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Sep 27, 2024
Primary completion
Nov 26, 2027 (estimated)
Completion
Mar 2, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK4532990

Start the discussion